Search

Displaying results 5651 - 5660 of 10000 in total
  1. Drug

    Finotonlimab

    go.drugbank.com/drugs/DB18859
    Investigational

    Finotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).

  2. Drug

    Lepunafusp alfa

    go.drugbank.com/drugs/DB19011
    Investigational

    Lepunafusp alfa is under investigation in clinical trial NCT04453085 (An Extension Study of JR-171-101 Study in Patients With MPS I).

  3. Drug

    Plinabulin

    go.drugbank.com/drugs/DB05992
    Investigational

  4. Drug

    Elsamitrucin

    go.drugbank.com/drugs/DB05129
    Investigational

    The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)

  5. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  6. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … Because Hly is only active at an acidic pH, similar to listeriolysin O, the deletion of urease C was also beneficial for Hly to have optimal bioactivity in the phagosome.

  7. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  8. Drug

    AMT-080

    go.drugbank.com/drugs/DB17846
    Experimental

    AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.

  9. Drug

    CTX130

    go.drugbank.com/drugs/DB18627
    Investigational

    CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

  10. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.